Crowdonomics
All companies
Scinovia logo

Scinovia

Operating

Scinovia Corp.

Healthcare · Technology · Raleigh, WY · Founded 2014

Mission to product state-of-art diagnostics to help doctos make more data-driven decisions

Post-money valuation ⓘ
$89.4M
As of Jun 2022 · from Reg CF Offering (2021) · pre-money + amount raised, not a traded price
Total raised
$11,525,964
Crowd $106K · Private $11.4M · 4 rounds since 2014
Latest share price
$2.85
Reg CF · Common Stock · Dec 2021 offering price

Financials

FY2019–FY2021 · from SEC filings · hover any figure for its source
$0
−$589K
2019
$0
−$731K
2020
$0
−$728K
2021
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019 reviewed
FY2020 reviewed
FY2021
Income statement
Revenue
$0
$0
$0
Cost of goods sold
$0
$0
$0
Net income
-$588,679
-$731,388
-$728,230
Taxes paid
$0
$0
$0
Balance sheet
Cash
$279,741
$110,738
$73,150
Accounts receivable
$0
$0
$0
Total assets
$1,360,287
$1,362,037
$1,268,206
Short-term debt
$223,528
$142,299
$385,680
Long-term debt
$64,566
$53,170
$25,050
Total liabilities
$288,094
$195,469
$410,730
Other
Headcount
—
10
10

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$89.3M
pre-money
Reg CF · Common · Dec 2021

Blue bars are the pre-money valuation the company stated for a priced round.

Share price over rounds

$2.85$1.425$0.6345
Nov 2021Dec 2021
Round offering price or verified disclosed saleDisclosed sale, unverified or year-only

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Cap table

Principal holders% as the filing states it, Dec 21, 2021

  • Owned Class A Accuflow Imaging LLC83.6 Common20.0%of company

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $106.3K / $1.1MInvestors 84Post-money $89.4M
Raised $3.8MInvestors 56

Team

5 people
Dr. Kim SteinmannFounder
Medical Advisor

* Pediatric Hematologist/Oncologist * Pediatric Emergency Medicine Kim is board certified in both Pediatric Emergency Medicine and Pediatric Hematology/Oncology. She received her M.D. from the St. Louis University School of Medicine and completed her Pediatric ER residency training at Cardinal Glennon Children’s Hospital in St. Louis. She then completed her Pediatric Hematology/Oncology fellowship at University of Michigan in Ann Arbor, Michigan. She brings extensive academic, teaching, and clinical experience from her 10+ years as a faculty/staff member at several institutions as well as 10+ years of industry experience, working on both solid and hematological malignancies with early to late phase clinical development of targeted therapies. Kim is a board member of the pediatric collaborative team. She has had publications in several peer reviewed journals and has presented scientific data at various national and international conferences and training events in oncology and emergency medicine. M.D., FCCP, FASCO

Dr. Randall WolfFounder
Surgeon Advisor

* Reknowned heart surgeon with over 40 years of experience performing heart bypass procedures * first heart bypass using DaVinci robot * Professor & Heart Surgeon, Houston Methodist * Inventor of Wolf Mini Maze for A-fib * Master Magician Randall K. Wolf, M.D., is a leading innovator in minimally invasive treatment of atrial fibrillation. The first North American heart surgeon to perform robotic assisted coronary bypass, Dr. Wolf has pioneered DaVinci cardiac surgery and a number of other cardiothoracic procedures including the Wolf Minimaze, endoscopic first rib resection and endoscopic thoracic spine surgery. Dr. Wolf has authored over 100 peer reviewed articles and book chapters. He has served as president of the International Society of Minimally Invasive Cardiothoracic Surgery (ISMICS) and president of the 21st Century Cardiothoracic Surgery Society. He has also served as Professor of Surgery at Ohio State University; Professor of Surgery and Biomedical Engineering at the University of Cincinnati; and Visiting Professor at The University of Texas. BA - Indiana University MD - Indiana University School of Medicine

Jeff HaagFounder
VP of Engineering

Jeff was a Founding Investor who brings over 30 years of experience in Embedded Real-Time Hardware and Software Development and Software Systems Architecture across a wide range of commercial platforms with millions of users. He has participated in all levels of Software Development, from coding to architecture, from managing small teams of developers to working with and managing complex architectures across Business Units. Jeff has a very strong background in all aspects of Production Delivery of quality hardware and software products from his career spanning several years at IBM, SquareD, and 3Com, as well as 20 years at Cisco Systems. He brings a very complete background of software systems with deep expertise in Device Management, Real-Time processing, Networking, Security, and Virtualization, wide general knowledge of mechanical and electrical engineering, as well as extensive experience managing technical customer relationships. MS Computer Science, North Carolina State University BS Electrical Engineering, Virginia Tech

Jim Sund, PhD, MBAFounder
CEO and Founder

Jim led the development and commercialization of a life science informatics platform that was licensed by Merck & Roche. He evaluated the commercial viability of hundreds inventions for NASA and universities. Jim mentored dozens of Duke graduate consulting practicums to solve challenges for Fortune clients. As part of Lockheed Martin, Jim managed contracts, systems engineering, and computer security for the US EPA National Computing Center. PhD - Electrical & Computer Engineering, Duke University MBA - Duke University BS - Chemistry, University of Florida. BS - Biology, University of Florida

James Bradley Sund, Sr.
CEO, Principal Executive Officer and Director, Principal Financial Officer and Principal Accounting Officer

Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFiled Form C-TR (terminated reporting)

Filed 1 of 5 annual reports (FY2021–FY2025)

84 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

  • Form C-TRSep 6, 20230001665160-23-001723
    EDGAR
  • Form DSep 13, 20220001627490-22-000004
    EDGAR
  • Form C-UAug 10, 20220001665160-22-002184
    EDGAR
  • Form C/AMay 26, 20220001665160-22-001705
    EDGAR
  • Form C/AMay 11, 20220001665160-22-001637
    EDGAR
  • Form C/AApr 29, 20220001665160-22-001170
    EDGAR
  • Form C-ARApr 25, 20220001665160-22-000769
    EDGAR
  • Form C/AApr 25, 20220001665160-22-000772
    EDGAR
Source: ManualCIK 0001627490WYShare price $2.85

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.